Repeated Stem Cell Injections Show Safety Promise for ALS Patients
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
Summary
Researchers at Hadassah Medical Organization conducted a Phase 1/2 clinical trial examining whether repeatedly injecting patients' own bone marrow stem cells directly into the spinal fluid could slow ALS progression. Twenty patients with confirmed ALS and relatively early-stage disease received four intrathecal injections of mesenchymal stem cells spaced three months apart. The primary focus was safety and tolerability, with secondary measures tracking disease progression. ALS currently has very limited treatment options, and stem cell therapies represent one of the more promising investigational avenues. This completed trial provides important data on whether repeated dosing of autologous MSCs is feasible without serious adverse events, which is a critical step before larger efficacy-focused trials can be designed. Results from this study could help shape the future of regenerative medicine approaches to neurodegenerative disease.
Detailed Summary
Amyotrophic lateral sclerosis remains one of medicine's most devastating diagnoses, with patients facing progressive motor neuron loss, paralysis, and a median survival of two to five years. Existing approved treatments offer only modest benefits, making the search for regenerative or disease-modifying therapies urgent. Mesenchymal stem cells have attracted significant interest because of their potential neuroprotective and anti-inflammatory properties, but the optimal dosing strategy — particularly whether repeated administrations are safe — has remained unclear.
This completed Phase 1/2 trial, sponsored by Hadassah Medical Organization in Israel, enrolled 20 patients aged 20 to 70 with a definitive ALS diagnosis, an ALS Functional Rating Scale Revised score of at least 20, and disease duration under three years. Each participant received four intrathecal injections of autologous bone marrow derived mesenchymal stem cells at three-month intervals — a protocol designed to test whether sustained exposure to MSCs might provide cumulative therapeutic benefit while remaining tolerable.
The primary endpoints centered on safety and tolerability, asking whether repeated lumbar puncture-based cell delivery produces serious adverse events. Secondary endpoints captured efficacy signals including functional decline rates, respiratory measures, and other disease progression markers. The autologous design — using each patient's own cells — reduces immunological rejection risk and sidesteps ethical concerns tied to donor-derived cells.
For clinicians, this trial matters because it directly addresses a practical barrier to MSC therapy: the uncertainty around repeated dosing. If four administrations prove well-tolerated, it opens the door to larger randomized controlled trials powered to detect meaningful slowing of disease progression.
Caveats are important. This is an open-label, single-center study with no control arm, making it impossible to attribute any observed stabilization to treatment rather than natural variation. The small sample of 20 patients limits generalizability, and full results including efficacy data have not been published in peer-reviewed literature based on available information.
Key Findings
- Four intrathecal MSC injections at 3-month intervals were evaluated for safety in 20 ALS patients.
- Autologous bone marrow-derived MSCs were used, minimizing immune rejection risk.
- Only patients with early-stage disease (ALS-FRS-R ≥20, duration <3 years) were enrolled.
- Trial is completed, providing foundational safety data to guide future larger efficacy trials.
- Phase 1/2 design allows preliminary efficacy signals to be captured alongside safety monitoring.
Methodology
Open-label, single-center Phase 1/2 trial with no control arm, enrolling 20 ALS patients who received four intrathecal autologous MSC injections spaced three months apart. Primary endpoints were safety and tolerability; secondary endpoints assessed functional and disease progression measures. The lack of randomization or blinding limits causal interpretation of any efficacy signals.
Study Limitations
The open-label, single-center design with no control group makes it impossible to separate treatment effects from natural disease variation or placebo response. The sample size of 20 patients is insufficient to draw efficacy conclusions. This summary is based on the abstract only, as full trial results and peer-reviewed publication were not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.